DHTKD1 and neoplasm: However, enhanced oncolytic adenoviruses can exploit these conditions; for example, HYPR-Ad is engineered to express E1A under HIF-1α control, a protein activated under hypoxic conditions, providing additional specificity for hypoxic tumor targeting [102].